{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '6.7.1.', 'Study Treatment Return', 'All used and unused ELLIPTA and DISKUS inhalers and albuterol/salbutamol will be', 'returned to GSK at the end of the study to be available for disposal. In some instances', 'for sites outside the US, study supplies will be disposed of locally either by the site, the', 'country medical department or third-party vendor. Detailed instructions for the return of', 'the study drug can be found in the SRM.', 'Study treatment will be collected at Visit 3, 4 and 5 or at the Early Withdrawal Visit, if', 'applicable.', 'For any ELLIPTA or DISKUS inhaler that fails to function properly, the subject should', 'return to the clinic as soon as possible to obtain a new inhaler. The site will contact the', 'RAMOS NG to obtain a new treatment pack number for the subject and dispense a new', \"study treatment kit from the site's investigational product supply as instructed by the\", 'RAMOS NG', 'In addition, any ELLIPTA that fails to function properly must be identified and returned', 'to GSK for testing.', '6.8.', 'Compliance with Study Treatment Administration', 'When subjects self-administer study treatment(s) at home, compliance with study', 'treatment(s) will be assessed through querying the subject during the site visits and', 'through study drug compliance assessed at Visits 2, 3, 4 and 5 documented in the source', 'documents and eCRF. A record of the number of ELLIPTA and DISKUS dispensed and', 'the number of doses inhaled by each subject must be maintained and reconciled with', 'study treatment and compliance records. Treatment start and stop dates, including dates', 'for treatment delays if any will also be recorded in the eCRF.', 'Compliance with the ELLIPTA inhaler will be determined by reviewing the dose counter', 'on the ELLIPTA. Compliance with the study DISKUS will be determined by reviewing', 'the dose counter on the DISKUS. Subjects should be >80% to <120% compliant on', 'taking study medication between each pair of on-treatment visits. Subjects who fall', 'outside this range should be re-educated on treatment compliance by their site. This re-', \"education should be documented in the subject's source document. If medication\", 'compliance repeatedly falls outside of acceptable ranges, the study sponsor/site monitor', 'must be contacted to discuss subject eligibility for continued participation in the study.', '6.9.', 'Treatment of Study Treatment Overdose', 'An overdose is defined as a dose greater than the total doses described in Section 6.1 and', 'Section 6.8 which results in clinical signs and symptoms. These should be recorded by', 'the investigator on the AE/SAE pages. In the event of an overdose of study medication,', 'the investigator should use clinical judgment in treating the overdose and contact the', 'study Medical Monitor.', '39']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'GSK is not recommending specific treatment guidelines for overdose and toxicity', 'management. The investigator is advised to refer to the relevant document(s) for detailed', 'information regarding warnings, precautions, contraindications, adverse events, and other', 'significant data pertaining to the study drug being used in this study. Such documents', 'may include, but may not be limited to, the approved product label for salmeterol', 'albuterol, UMEC and UMEC/VI or equivalent document provided by GSK.', 'Decisions regarding dose interruptions or modifications will be made by the investigator', 'in consultation with the Medical Monitor based on the clinical evaluation of the subject.', '6.10.', 'Treatment after the End of the Study', 'Subjects will not receive any additional treatment from GSK after completion of the', 'study, since the study treatments are commercially available.', 'The investigator is responsible for ensuring that consideration has been given to the post-', \"study care of the subject's medical condition, post-study treatment.\", '6.11.', 'Concomitant Medications and Non-Drug Therapies', 'All COPD medications used within 30 days prior to Pre-Screening (Visit 0) and onwards', 'should be recorded in the eCRF including any changes in medications. Beginning at', 'Visit 1 and throughout the rest of the study, all medications should be recorded in the', 'eCRF including any changes. Study provided albuterol/salbutamol and double-blinded', 'study drug should not be recorded in the eCRF. The minimum requirement includes but', 'is not limited to drug name, dose, route and the dates of administration. Medications', 'initiated after completion of Visit 5 or the Early Withdrawal Visit will not be recorded in', 'the eCRF, with the exception of those used to treat a COPD exacerbation or SAE that', 'occurs between Visit 5 (or the Early Withdrawal Visit) and the follow-up contact at tivit', '6.', '6.11.1.', 'Permitted Medications and Non-Drug Therapies', 'The following relevant medications are permitted during this study:', 'Study-provided albuterol/salbutamol for use as relief medication throughout the', 'run-in and treatment periods', 'Mucolytics such as acetylcysteine', 'Medications for rhinitis (e.g. intranasal corticosteroids, antihistamines, cromolyn,', 'nedocromil, nasal decongestants)', 'Influenza vaccine', 'pneumococcal vaccine', 'Antibiotics for short term treatment (<14 days) of acute infections including', 'COPD exacerbations', 'Systemic corticosteroids for short term (<14 consecutive days) treatment of', 'COPD exacerbations', '40']\n\n###\n\n", "completion": "END"}